These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35551212)

  • 1. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
    Joshi SR; Atabay EK; Liu J; Ding Y; Briscoe SD; Alexander MJ; Andre P; Kumar R; Li G
    Front Cardiovasc Med; 2023; 10():1064290. PubMed ID: 36910526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension.
    Yung LM; Yang P; Joshi S; Augur ZM; Kim SSJ; Bocobo GA; Dinter T; Troncone L; Chen PS; McNeil ME; Southwood M; Poli de Frias S; Knopf J; Rosas IO; Sako D; Pearsall RS; Quisel JD; Li G; Kumar R; Yu PB
    Sci Transl Med; 2020 May; 12(543):. PubMed ID: 32404506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
    Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
    Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
    [No Abstract]   [Full Text] [Related]  

  • 10. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
    Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
    Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective.
    Wang RR; Yuan TY; Wang JM; Chen YC; Zhao JL; Li MT; Fang LH; Du GH
    Pharmacol Res; 2022 Jun; 180():106238. PubMed ID: 35504356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Mendes-Ferreira P; Adão R; Brás-Silva C; Kinsella BT
    Eur J Pharmacol; 2020 Dec; 889():173658. PubMed ID: 33121950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension.
    Frid MG; McKeon BA; Thurman JM; Maron BA; Li M; Zhang H; Kumar S; Sullivan T; Laskowsky J; Fini MA; Hu S; Tuder RM; Gandjeva A; Wilkins MR; Rhodes CJ; Ghataorhe P; Leopold JA; Wang RS; Holers VM; Stenmark KR
    Am J Respir Crit Care Med; 2020 Jan; 201(2):224-239. PubMed ID: 31545648
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging biologics for the treatment of pulmonary arterial hypertension.
    Hye T; Hossain MR; Saha D; Foyez T; Ahsan F
    J Drug Target; 2023 Jun; 31(5):1-15. PubMed ID: 37026714
    [TBL] [